Does Rallies show Form 4 insider transactions for CLYM?

Yes. Rallies tracks CLYM insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is CLYM research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CLYM. It does not provide personalized investment advice.

CLYM (Climb Bio, Inc. Common Stock) Stock Analysis - Insider Trades

Climb Bio, Inc. Common Stock (CLYM) is a publicly traded Healthcare sector company. As of May 21, 2026, CLYM trades at $10.31 with a market cap of $565.73M and a P/E ratio of -11.69. CLYM moved +9.33% today. Year to date, CLYM is +197.18%; over the trailing twelve months it is +748.39%. Its 52-week range spans $1.05 to $12.48. Analyst consensus is strong buy with an average price target of $19.67. Rallies surfaces CLYM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading CLYM stock inside the company?

Recent CLYM insider activity includes Thomas Stephen Basil sold 16.31K, Thomas Stephen Basil sold 33.69K, Thomas Stephen Basil sold 10.00K, Thomas Stephen Basil sold 90.00K, and RA CAPITAL MANAGEMENT, L.P. bought 7.11K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

CLYM Key Metrics

Key financial metrics for CLYM
Metric	Value
Price	$10.31
Market Cap	$565.73M
P/E Ratio	-11.69
EPS	$-0.88
Dividend Yield	0.00%
52-Week High	$12.48
52-Week Low	$1.05
Volume	59
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-59.85M
Gross Margin	0.00%

Recent CLYM Insider Trades

Thomas Stephen Basil sold 16.31K (~$114.29K) on Feb 26, 2026.
Thomas Stephen Basil sold 33.69K (~$235.96K) on Feb 25, 2026.
Thomas Stephen Basil sold 10.00K (~$58.14K) on Feb 13, 2026.
Thomas Stephen Basil sold 90.00K (~$470.99K) on Feb 12, 2026.
RA CAPITAL MANAGEMENT, L.P. bought 7.11K (~$24.89K) on Jan 5, 2026.

Latest CLYM News

Climb Bio to present budoprutug Phase 1b/2a 250mg data at EHA June 2026 — May 14, 2026
Climb Bio Raises $110M, Budoprutug SC Shows Robust B-Cell Depletion, pMN Fast Track — May 7, 2026
Climb Bio’s Budoprutug Subcutaneous Shows Robust B-Cell Depletion, Fast Track for pMN — May 5, 2026
Climb Bio Secures $110M in Private Placement via 9.48M Shares at $9.50 — Apr 28, 2026
Climb Bio Secures FDA Fast Track for Budoprutug After 100% B-Cell Depletion — Apr 7, 2026

CLYM Analyst Consensus

13 analysts cover CLYM: 0 strong buy, 13 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $19.67.

Common questions about CLYM

Who is trading CLYM stock inside the company?: Recent CLYM insider activity includes Thomas Stephen Basil sold 16.31K, Thomas Stephen Basil sold 33.69K, Thomas Stephen Basil sold 10.00K, Thomas Stephen Basil sold 90.00K, and RA CAPITAL MANAGEMENT, L.P. bought 7.11K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for CLYM?: Yes. Rallies tracks CLYM insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is CLYM research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CLYM. It does not provide personalized investment advice.